- Home
- TROO vs AGEN Comparison
TROO vs AGEN Comparison
Compare TROO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- AGEN
- Stock Information
- Founded
- TROO 2005
- AGEN 1994
- Country
- TROO Hong Kong
- AGEN United States
- Employees
- TROO N/A
- AGEN N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TROO Technology
- AGEN Health Care
- Exchange
- TROO Nasdaq
- AGEN Nasdaq
- Market Cap
- TROO N/A
- AGEN 87.7M
- IPO Year
- TROO N/A
- AGEN 2000
- Fundamental
- Price
- TROO $0.66
- AGEN $7.27
- Analyst Decision
- TROO
- AGEN Buy
- Analyst Count
- TROO 0
- AGEN 4
- Target Price
- TROO N/A
- AGEN $13.00
- AVG Volume (30 Days)
- TROO 17.6K
- AGEN 1.4M
- Earning Date
- TROO 07-22-2025
- AGEN 08-07-2025
- Dividend Yield
- TROO N/A
- AGEN N/A
- EPS Growth
- TROO N/A
- AGEN N/A
- EPS
- TROO N/A
- AGEN N/A
- Revenue
- TROO $10,073,000.00
- AGEN $99,524,000.00
- Revenue This Year
- TROO N/A
- AGEN $12.69
- Revenue Next Year
- TROO N/A
- AGEN N/A
- P/E Ratio
- TROO N/A
- AGEN N/A
- Revenue Growth
- TROO 182.24
- AGEN N/A
- 52 Week Low
- TROO $0.49
- AGEN $1.38
- 52 Week High
- TROO $4.89
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- TROO 43.49
- AGEN 68.42
- Support Level
- TROO $0.61
- AGEN $4.78
- Resistance Level
- TROO $0.73
- AGEN $6.20
- Average True Range (ATR)
- TROO 0.05
- AGEN 0.62
- MACD
- TROO -0.01
- AGEN 0.10
- Stochastic Oscillator
- TROO 21.43
- AGEN 98.90
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).